UroGen Non Operating Income Net Other vs Total Other Income Expense Net Analysis

URGN Stock

USD 13.22 0.01 0.08%

UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Non Operating Income Net Other and its Total Other Income Expense Net accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Non Operating Income Net Other vs Total Other Income Expense Net

Non Operating Income Net Other vs Total Other Income Expense Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Non Operating Income Net Other account and Total Other Income Expense Net. At this time, the significance of the direction appears to have pay attention.

The correlation between UroGen Pharma's Non Operating Income Net Other and Total Other Income Expense Net is -0.9. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Total Other Income Expense Net in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Non Operating Income Net Other and Total Other Income Expense Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of UroGen Pharma are associated (or correlated) with its Total Other Income Expense Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Other Income Expense Net has no effect on the direction of Non Operating Income Net Other i.e., UroGen Pharma's Non Operating Income Net Other and Total Other Income Expense Net go up and down completely randomly.

Correlation Coefficient

-0.9

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Non Operating Income Net Other

Total Other Income Expense Net

Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 18th of May 2024, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	17.3M	1.0M	1.7M	3.0M
Interest Income	365K	938K	2.4M	1.9M

Depreciation And Amortization Interest Income

UroGen Pharma fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Common Stock Shares Outstanding	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity	Property Plant And Equipment Gross
Total Assets		0.87	0.22	0.13	-0.76	0.82	0.79	0.62	0.58	0.99	0.88	0.8	0.91	0.92	0.88	-0.13	0.69	0.91	0.99	0.95	0.85	0.83	0.53	0.92	0.92	0.76
Total Current Liabilities	0.87		-0.17	-0.26	-0.96	0.76	0.77	0.88	0.85	0.9	0.99	0.64	0.9	0.92	0.81	0.06	0.42	0.79	0.88	0.92	0.66	0.72	0.81	0.92	0.94	0.88
Total Stockholder Equity	0.22	-0.17		0.99	0.4	0.11	0.18	-0.59	-0.63	0.13	-0.11	0.55	0.0	-0.05	0.22	-0.79	0.53	0.24	0.23	0.05	0.49	0.2	-0.68	-0.05	-0.08	-0.02
Net Tangible Assets	0.13	-0.26	0.99		0.48	0.04	0.09	-0.65	-0.71	0.04	-0.21	0.48	-0.08	-0.13	0.16	-0.77	0.47	0.18	0.13	-0.02	0.42	0.14	-0.75	-0.12	-0.16	-0.15
Retained Earnings	-0.76	-0.96	0.4	0.48		-0.65	-0.66	-0.97	-0.94	-0.81	-0.93	-0.48	-0.85	-0.9	-0.73	-0.26	-0.27	-0.67	-0.76	-0.85	-0.47	-0.61	-0.91	-0.9	-0.92	-0.8
Accounts Payable	0.82	0.76	0.11	0.04	-0.65		0.84	0.57	0.54	0.87	0.79	0.46	0.82	0.68	0.57	-0.24	0.3	0.89	0.85	0.85	0.86	0.84	0.49	0.74	0.74	0.5
Cash	0.79	0.77	0.18	0.09	-0.66	0.84		0.51	0.47	0.85	0.8	0.63	0.83	0.76	0.65	-0.43	0.25	0.84	0.84	0.84	0.78	0.8	0.41	0.78	0.78	0.65
Other Current Assets	0.62	0.88	-0.59	-0.65	-0.97	0.57	0.51		0.98	0.68	0.84	0.28	0.75	0.79	0.6	0.44	0.11	0.56	0.61	0.74	0.31	0.51	0.97	0.79	0.81	0.67
Total Liab	0.58	0.85	-0.63	-0.71	-0.94	0.54	0.47	0.98		0.64	0.82	0.2	0.69	0.73	0.51	0.52	0.13	0.48	0.59	0.68	0.29	0.45	1.0	0.72	0.75	0.7
Total Current Assets	0.99	0.9	0.13	0.04	-0.81	0.87	0.85	0.68	0.64		0.91	0.74	0.94	0.93	0.85	-0.13	0.56	0.94	0.98	0.98	0.83	0.86	0.59	0.94	0.94	0.75
Common Stock	0.88	0.99	-0.11	-0.21	-0.93	0.79	0.8	0.84	0.82	0.91		0.64	0.89	0.89	0.78	0.01	0.42	0.83	0.91	0.93	0.7	0.75	0.78	0.9	0.92	0.87
Property Plant Equipment	0.8	0.64	0.55	0.48	-0.48	0.46	0.63	0.28	0.2	0.74	0.64		0.69	0.75	0.91	-0.42	0.77	0.69	0.79	0.72	0.72	0.64	0.14	0.72	0.7	0.68
Common Stock Shares Outstanding	0.91	0.9	0.0	-0.08	-0.85	0.82	0.83	0.75	0.69	0.94	0.89	0.69		0.91	0.82	-0.07	0.43	0.83	0.88	0.92	0.69	0.85	0.64	0.92	0.93	0.74
Other Current Liab	0.92	0.92	-0.05	-0.13	-0.9	0.68	0.76	0.79	0.73	0.93	0.89	0.75	0.91		0.91	0.03	0.52	0.81	0.9	0.94	0.65	0.73	0.69	0.99	0.99	0.79
Property Plant And Equipment Net	0.88	0.81	0.22	0.16	-0.73	0.57	0.65	0.6	0.51	0.85	0.78	0.91	0.82	0.91		-0.12	0.69	0.77	0.85	0.86	0.7	0.7	0.46	0.89	0.87	0.7
Net Debt	-0.13	0.06	-0.79	-0.77	-0.26	-0.24	-0.43	0.44	0.52	-0.13	0.01	-0.42	-0.07	0.03	-0.12		-0.09	-0.29	-0.19	-0.12	-0.45	-0.23	0.58	-0.02	0.01	0.0
Non Current Assets Total	0.69	0.42	0.53	0.47	-0.27	0.3	0.25	0.11	0.13	0.56	0.42	0.77	0.43	0.52	0.69	-0.09		0.43	0.64	0.46	0.64	0.37	0.09	0.47	0.46	0.55
Long Term Debt	0.91	0.79	0.24	0.18	-0.67	0.89	0.84	0.56	0.48	0.94	0.83	0.69	0.83	0.81	0.77	-0.29	0.43		0.92	0.95	0.86	0.88	0.43	0.85	0.84	0.57
Cash And Short Term Investments	0.99	0.88	0.23	0.13	-0.76	0.85	0.84	0.61	0.59	0.98	0.91	0.79	0.88	0.9	0.85	-0.19	0.64	0.92		0.95	0.89	0.82	0.53	0.9	0.9	0.79
Common Stock Total Equity	0.95	0.92	0.05	-0.02	-0.85	0.85	0.84	0.74	0.68	0.98	0.93	0.72	0.92	0.94	0.86	-0.12	0.46	0.95	0.95		0.79	0.84	0.62	0.97	0.97	0.73
Short Term Investments	0.85	0.66	0.49	0.42	-0.47	0.86	0.78	0.31	0.29	0.83	0.7	0.72	0.69	0.65	0.7	-0.45	0.64	0.86	0.89	0.79		0.73	0.23	0.68	0.66	0.54
Long Term Debt Total	0.83	0.72	0.2	0.14	-0.61	0.84	0.8	0.51	0.45	0.86	0.75	0.64	0.85	0.73	0.7	-0.23	0.37	0.88	0.82	0.84	0.73		0.4	0.76	0.75	0.55
Non Current Liabilities Total	0.53	0.81	-0.68	-0.75	-0.91	0.49	0.41	0.97	1.0	0.59	0.78	0.14	0.64	0.69	0.46	0.58	0.09	0.43	0.53	0.62	0.23	0.4		0.67	0.71	0.65
Capital Surpluse	0.92	0.92	-0.05	-0.12	-0.9	0.74	0.78	0.79	0.72	0.94	0.9	0.72	0.92	0.99	0.89	-0.02	0.47	0.85	0.9	0.97	0.68	0.76	0.67		1.0	0.74
Other Stockholder Equity	0.92	0.94	-0.08	-0.16	-0.92	0.74	0.78	0.81	0.75	0.94	0.92	0.7	0.93	0.99	0.87	0.01	0.46	0.84	0.9	0.97	0.66	0.75	0.71	1.0		0.78
Property Plant And Equipment Gross	0.76	0.88	-0.02	-0.15	-0.8	0.5	0.65	0.67	0.7	0.75	0.87	0.68	0.74	0.79	0.7	0.0	0.55	0.57	0.79	0.73	0.54	0.55	0.65	0.74	0.78

Click cells to compare fundamentals

UroGen Pharma Account Relationship Matchups

UroGen Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	202.4M	122.0M	119.7M	136.2M	178.3M	98.8M
Total Current Liabilities	19.5M	21.4M	22.4M	23.9M	31.2M	32.8M
Total Stockholder Equity	180.3M	96.4M	8.4M	(88.7M)	(65.2M)	(62.0M)
Net Tangible Assets	180.3M	96.4M	8.4M	(89.4M)	(102.8M)	(97.6M)
Retained Earnings	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(679.3M)	(645.4M)
Accounts Payable	4.7M	3.3M	5.8M	5.5M	6.5M	4.3M
Cash	49.7M	103.9M	44.4M	55.4M	95.8M	53.4M
Other Current Assets	1.0M	3.4M	7.5M	11.1M	10.3M	10.8M
Total Liab	22.1M	25.7M	111.3M	225.0M	243.5M	255.7M
Total Current Assets	148.6M	115.6M	114.4M	128.9M	169.2M	90.2M
Common Stock	57K	60K	61K	63K	89K	93.5K
Property Plant Equipment	4.7M	4.2M	2.0M	1.3M	1.5M	1.7M
Common Stock Shares Outstanding	20.5M	21.8M	22.3M	22.8M	28.8M	18.3M
Other Current Liab	14.8M	15.9M	12.8M	16.8M	19.5M	10.8M
Property Plant And Equipment Net	4.7M	4.2M	3.1M	3.7M	2.4M	2.6M
Net Debt	(47.1M)	(102.4M)	(44.0M)	43.7M	4.4M	4.6M
Non Current Assets Total	53.8M	6.4M	5.4M	6.7M	9.1M	10.4M
Cash And Short Term Investments	147.1M	103.9M	89.8M	100.0M	137.8M	96.8M
Common Stock Total Equity	57K	60K	61K	63K	72.5K	45.9K
Liabilities And Stockholders Equity	202.4M	122.0M	119.7M	136.2M	178.3M	119.8M
Non Current Liabilities Total	2.6M	4.2M	89.0M	201.1M	212.3M	222.9M
Capital Surpluse	408.0M	452.5M	475.7M	487.8M	561.0M	307.7M
Other Stockholder Equity	408.0M	452.5M	475.7M	488.4M	614.0M	348.8M
Property Plant And Equipment Gross	4.7M	4.2M	2.0M	1.3M	6.3M	6.6M
Accumulated Other Comprehensive Income	276K	271K	(25K)	(107K)	12K	12.6K
Non Currrent Assets Other	487K	289K	1.5M	2.7M	2.0M	1.1M
Other Assets	487K	289K	29.9K	620K	713K	367.9K
Net Invested Capital	180.3M	96.4M	8.4M	8.2M	33.3M	55.5M
Net Working Capital	129.2M	94.2M	92.0M	105.0M	138.0M	112.3M
Retained Earnings Total Equity	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(519.4M)	(545.4M)
Capital Stock	57K	60K	61K	63K	89K	68.6K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for UroGen Stock analysis

When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.

	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.22)

Revenue Per Share

2.688

Quarterly Revenue Growth

0.092

Return On Assets

(0.28)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Non Operating Income Net Other vs Total Other Income Expense Net Analysis

Non Operating Income Net Other vs Total Other Income Expense Net

Non Operating Income Net Other vs Total Other Income Expense Net Correlation Analysis

Correlation Coefficient

Non Operating Income Net Other

Total Other Income Expense Net

UroGen Pharma fundamental ratios Correlations

UroGen Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

UroGen Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for UroGen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Other Stockholder Equity	+ 1.0	Capital Surpluse
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Common Stock	+ 0.99	Total Current Liabilities
Net Tangible Assets	+ 0.99	Total Stockholder Equity

Other Current Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities
Total Liab	- 0.94	Retained Earnings
Common Stock	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.92	Retained Earnings
Non Current Liabilities Total	- 0.91	Retained Earnings